Mechanisms and Molecular Targets of Artemisinin in Cancer Treatment

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590.
   PubMed Web of Science ®Google Scholar
• Sharma P, Mehta M, Dhanjal DS, Kaur S, Gupta G, Singh H, et al. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem Biol Interact. 2019; 309:108720. doi:10.1016/j.cbi.2019.06.033.
   PubMed Web of Science ®Google Scholar
• Luo Y, Sun X, Huang L, Yan J, Yu B-Y, Tian J. Artemisinin-based smart nanomedicines with self-supply of ferrous ion to enhance oxidative stress for specific and efficient cancer treatment. ACS Appl Mater Interfaces. 2019;11(33):29490–7. doi:10.1021/acsami.9b07390.
   PubMed Web of Science ®Google Scholar
• Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, et al. Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021;104:110050. doi:10.1016/j.pnpbp.2020.110050.
   PubMed Web of Science ®Google Scholar
• Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34(1):1–10. doi:10.1186/s13046-015-0221-y.
   PubMedGoogle Scholar
• Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: A comprehensive review of recent advances. Cancer Manag Res. 2019;11:3295–313. doi:10.2147/CMAR.S200059.
   PubMed Web of Science ®Google Scholar
• Yoshida GJ. Emerging roles of Myc in stem cell biology and novel tumor therapies. J Exp Clin Cancer Res. 2018;37(1):173. doi:10.1186/s13046-018-0835-y.
   PubMedGoogle Scholar
• Dong LH, Cheng S, Zheng Z, Wang L, Shen Y, Shen ZX, et al. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J Hematol Oncol. 2013;6(1):53. doi:10.1186/1756-8722-6-53.
   PubMedGoogle Scholar
• Faiva E, Hashim HT, Ramadhan MA, Musa SK, Bchara J, Tuama YD, et al. Drug supply shortage in Nigeria during COVID 19: efforts and challenges. J Pharm Policy and Pract. 2021;14(1):17. doi:10.1186/s40545-021-00302-1.
   PubMedGoogle Scholar
• Yang Y-M, Chen L-N, Qu S-Q, Deng S-Q, Liu H, Wang X, et al. [Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection]. Zhongguo Zhong Yao Za Zhi. 2020;45(24):6053–64. doi:10.19540/j.cnki.cjcmm.20200828.601.
   PubMedGoogle Scholar
• Sehailia M, Chemat S. Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19. J Biomol Struc Dyn. 2020;11: 1–11.
   Google Scholar
• Krishna S, Augustin Y, Wang J, Xu C, Staines HM, Platteeuw H, et al. Repurposing antimalarials to tackle the COVID-19 pandemic. Trends Parasitol. 2021;37(1):8–11. doi:10.1016/j.pt.2020.10.003.
   PubMed Web of Science ®Google Scholar
• Grazzia N, Boaventura S, Garcia VL, Gadelha FR, Miguel DC. Dihydroartemisinin, an active metabolite of artemisinin, interferes with Leishmania braziliensis mitochondrial bioenergetics and survival. Parasitol Res. 2021;120(2):705–13. doi:10.1007/s00436-020-07019-1.
   PubMed Web of Science ®Google Scholar
• Cui H, Chen X, Bai M, Han D, Lin L, Dong M. Multipathway antibacterial mechanism of a nanoparticle-supported artemisinin promoted by nitrogen plasma treatment. ACS Appl Mater Interfaces. 2019;11(50):47299–310. doi:10.1021/acsami.9b15124.
   PubMed Web of Science ®Google Scholar
• Oiknine-Djian E, Bar-On S, Laskov I, Lantsberg D, Haynes RK, Panet A, et al. Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. Antiviral Res. 2019; 172:104639. doi:10.1016/j.antiviral.2019.104639.
   PubMed Web of Science ®Google Scholar
• Kim S-K, Choe J-Y, Park K-Y. Anti-inflammatory effect of artemisinin on uric acid-induced NLRP3 inflammasome activation through blocking interaction between NLRP3 and NEK7. Biochem Biophys Res Commun. 2019;517(2):338–45. doi:10.1016/j.bbrc.2019.07.087.
   PubMed Web of Science ®Google Scholar
• Charlie-Silva I, Fraceto LF, de Melo NFS. Progress in nano-drug delivery of artemisinin and its derivatives: towards to use in immunomodulatory approaches. Artif Cells Nanomed Biotechnol. 2018;46(Sup 3):S611–S620.
   PubMedGoogle Scholar
• Elisei LMS, Moraes TR, Malta IH, Charlie-Silva I, Sousa IMO, Veras FP, Foglio MA, et al. Antinociception induced by artemisinin nanocapsule in a model of postoperative pain via spinal TLR4 inhibition. Inflammopharmacology. 2020;28(6):1537–1551.
   PubMed Web of Science ®Google Scholar
• Rai SK, Apoorva, Rai KK, et al. New perspectives of the artemisia annua bioactive compounds as an affordable cure in treatment of malaria and cancer. Natural bioactive compounds: technological advancements 2021;299–315.
   Google Scholar
• Li Z, Wu X, Wang W, Gai C, Zhang W, Li W, et al. Fe(II) and tannic acid-cloaked MOF as carrier of artemisinin for supply of ferrous ions to enhance treatment of triple-negative breast cancer. Nanoscale Res Lett. 2021;16(1):37. doi:10.1186/s11671-021-03497-z.
   PubMed Web of Science ®Google Scholar
• Yameogo JBG, et al. Pharmacokinetic study of intravenously administered artemisinin-loaded surface-decorated amphiphilic gamma-cyclodextrin nanoparticles. Mater Sci Eng C Mater Biol Appl. 2020;106:6.
   Web of Science ®Google Scholar
• Kumari K, Keshari S, Sengupta D, Sabat SC, Mishra SK. Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment. BMC Cancer. 2017; 17(1):858. doi:10.1186/s12885-017-3863-7.
   PubMed Web of Science ®Google Scholar
• J Dong, Chen Y, Yang W, et al. Antitumor and anti-angiogenic effects of artemisinin on breast tumor xenografts in nude mice. Research in Veterinary Science. 2020;129:66–69.
   PubMed Web of Science ®Google Scholar
• Botta L, et al. Artemisinin derivatives with antimelanoma activity show inhibitory effect against Human DNA topoisomerase 1. ACS Med Chem Lett. 2020;11(5):1035–1040.
   PubMed Web of Science ®Google Scholar
• B YZA, et al. Structural optimization and biological evaluation for novel artemisinin derivatives against liver and ovarian cancers. Euro J Med Chem. 2020;211:113000.
   PubMed Web of Science ®Google Scholar
• Synthesis of tamoxifen‐artemisinin and estrogen‐artemisinin hybrids highly potent against breast and prostate cancer. J Chem Med Chem. 2020;15(15):1473–1479.
   Google Scholar
• Tong Y, et al. Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling. Oncotarget. 2016;7(21):31413–31428.
   PubMedGoogle Scholar
• Lin R, Zhang Z, Chen L, Zhou Y, Zou P, Feng C, et al. Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells. Cancer Lett. 2016;381(1):165–75. doi:10.1016/j.canlet.2016.07.033.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang L, Hao M. Effect of artemisinin on proliferation and apoptosis-related protein expression in vivo and in vitro. Saudi J Biol Sci. 2018;25(7):1488–1493.
   PubMed Web of Science ®Google Scholar
• Huang Z, Huang X, Jiang D, Zhang Y, Huang B, Luo G. Dihydroartemisinin inhibits cell proliferation by induced G1 arrest and apoptosis in human nasopharyngealcarcinoma cells. J Cancer Res Ther. 2016; 12(1):244–7. doi:10.4103/0973-1482.151855.
   PubMed Web of Science ®Google Scholar
• Bicheng Z, et al. Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation. Oncol Lett. 2018;15:7531–7536.
   PubMed Web of Science ®Google Scholar
• Li B, Bu S, Sun J, Guo Y, Lai D. Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. Acta Biochim Biophys Sin. 2018;50(12):1227–35. doi:10.1093/abbs/gmy125.
   Google Scholar
• Ma Q, Liao H, Xu L, et al. Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin. Chinese Medicine. 2020;15(1):115–132.
   Google Scholar
• Jianguang  , et al. Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis. Chin Med. 2016;15:37.
   Google Scholar
• Hu X, et al. Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Commun Biol. 2021;4(1):72.
   PubMed Web of Science ®Google Scholar
• Malla RR, Kamal MAJCMC. ROS-responsive nanomedicine: towards targeting the breast tumor microenvironment. Curr Med Chem. 2021;6:59.
   Google Scholar
• Bassiouni W, Ali MAM, Schulz RJTFJ. Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS J. 2021:15:701.
   PubMed Web of Science ®Google Scholar
• Cao J, Liu X, Yang Y, Wei B, Li Q, Mao G, et al. Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS/p53/BAI1 signaling pathway. Angiogenesis. 2020;23(3):325–12. doi:10.1007/s10456-020-09707-z.
   PubMed Web of Science ®Google Scholar
• Li L, Wu J, Weng S, Yang L, Wang H, Xu Y, et al. Fourier transform infrared spectroscopy monitoring of dihydroartemisinin-induced growth inhibition in ovarian cancer cells and normal ovarian surface epithelial cells. CMAR. 2020;12:653–61. doi:10.2147/CMAR.S240285.
   Google Scholar
• Liang R, Chen W, Chen X-Y, Fan H-N, Zhang J, Zhu J-S. Dihydroartemisinin inhibits the tumorigenesis and invasion of gastric cancer by regulating STAT1/KDR/MMP9 and P53/BCL2L1/CASP3/7 pathways. Pathol Res Pract. 2021;218:153318. doi:10.1016/j.prp.2020.153318.
   PubMed Web of Science ®Google Scholar
• Chen R, et al. Dihydroartemisinin prevents progression and metastasis of head and neck squamous cell carcinoma by inhibiting polarization of macrophages in tumor microenvironment. Onco Targets Ther. 2020;13:3375–3387.
   PubMed Web of Science ®Google Scholar
• Yao Y, et al. Correction to: Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer. J Exp Clin Cancer Res. 2019;38(1):451.
   PubMed Web of Science ®Google Scholar
• Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–85. doi:10.1016/j.cell.2017.09.021.
   PubMed Web of Science ®Google Scholar
• Wan J, et al. Iron toxicity, lipid peroxidation and ferroptosis after intracerebral haemorrhage. Stroke Vasc Neurol. 2019;4(2):svn-2018-000205.
   Google Scholar
• B YJHA, et al. Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials. 2020;241:119911.
   PubMed Web of Science ®Google Scholar
• Eling N, et al. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience. 2015;2(5):517–532.
   PubMedGoogle Scholar
• A HNF, et al. Dihydroartemisinin inhibits the growth and invasion of gastric cancer cells by regulating cyclin D1-CDK4-Rb signaling. Pathol Res Pract. 216(2):152795.
   PubMed Web of Science ®Google Scholar
• Mancias JD, et al. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife. 2015;4:e10308.
   PubMed Web of Science ®Google Scholar
• Yoshida GJJJoHO. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol. 2017;10:67.
   PubMed Web of Science ®Google Scholar
• Levy JMM, Towers CG, Thorburn AJNRC. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–542.
   PubMed Web of Science ®Google Scholar
• Chen X, He L-Y, Lai S, He Y. Dihydroartemisinin inhibits the migration of esophageal cancer cells by inducing autophagy. Oncol Lett. 2020;20(4) :1. doi:10.3892/ol.2020.11955.
   PubMed Web of Science ®Google Scholar
• Wu X, Liu Y, Zhang E, Chen J, Huang X, Yan H, et al. Dihydroartemisinin modulates apoptosis and autophagy in multiple myeloma through the P38/MAPK and Wnt/β -catenin signaling pathways. Oxid Med Cell Longev. 2020; 2020(4):6096312–6096391. doi:10.1155/2020/6096391.
   Google Scholar
• Jia G, Kong R, Ma Z-B, Han B, Wang Y-W, Pan S-H, et al. The activation of c-Jun NH2-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells. J Exp Clin Cancer Res. 2014;33(1):8. doi:10.1186/1756-9966-33-8.
   PubMed Web of Science ®Google Scholar
• Qian Z, et al. Autophagy plays a protective role in Mn-induced toxicity in PC12 cells. Toxicology. 2018; 394:45–53.
   PubMed Web of Science ®Google Scholar
• Yanhua M, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34.
   PubMed Web of Science ®Google Scholar
• Minghui G, et al. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26(9):1021–1032.
   PubMed Web of Science ®Google Scholar
• Du J, Wang T, Li Y, Zhou Y, Wang X, Yu X, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin - ScienceDirect. Free Radic Biol Med. 2019;131:356–369. doi:10.1016/j.freeradbiomed.2018.12.011.
   PubMed Web of Science ®Google Scholar
• Olsman M, et al. Focused ultrasound and microbubble treatment increases delivery of transferrin receptor-targeting liposomes to the brain. Ultrasound Med Biol 2021;47(5):1343–1355.
   PubMed Web of Science ®Google Scholar
• Vico GD, et al. Expression of transferrin receptor-1 (TFR-1) in canine osteosarcomas. Vet Med Sci. 2020;6(3):272–276.
   PubMed Web of Science ®Google Scholar
• Zhang H, et al. Enhancement of cytotoxicity of artemisinin toward cancer cells by transferrin-mediated carbon nanotubes nanoparticles. J Drug Target. 2015;23(6):552–567.
   PubMed Web of Science ®Google Scholar
• Leto I, Coronnello M, Righeschi C, Bergonzi MC, Mini E, Bilia AR. Enhanced efficacy of artemisinin loaded in transferrin‐conjugated liposomes versus stealth liposomes against HCT‐8 colon cancer cells. Chem Med Chem. 2016;11(16):1745–1751. doi:10.1002/cmdc.201500586.
   Google Scholar
• Emami J, et al. Targeted nanostructured lipid carrier for brain delivery of artemisinin: design, preparation, characterization, optimization and cell toxicity. J Pharm Pharm Sci. 2018;21(1s):225s–241s.
   PubMedGoogle Scholar
• Liu K, Dai L, Li C, Liu J, Wang L, Lei J. Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate. Sci Rep. 2016; 6:29461. doi:10.1038/srep29461.
   PubMed Web of Science ®Google Scholar
• Xueqin S, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst. 2002;94(8):585–591.
   PubMedGoogle Scholar
• B MAAA, et al. Targeting PI3K/Akt/mTOR signaling pathway by polyphenols: Implication for cancer therapy. Life Sci. 2020;255:117481.
   PubMed Web of Science ®Google Scholar
• Jean S, Kiger AAJJoCS. Classes of phosphoinositide 3-kinases at a glance. J Cell Sci. 2014; =127(Pt 5):923–928. doi:10.1242/jcs.093773.
   PubMed Web of Science ®Google Scholar
• Park  , et al. Pomolic acid suppresses HIF1 alpha/VEGF-mediated angiogenesis by targeting p38-MAPK and mTOR signaling cascades. Phytomedicine. 2016;23(14):1716–1726.
   PubMed Web of Science ®Google Scholar
• Marquard FE, Jücker M. Pharmacology, PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol. 2020;172:113729. doi:10.1016/j.bcp.2019.113729.
   PubMed Web of Science ®Google Scholar
• Jensen K. Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax. Exp Biol Med. 2019;244(8):621–629.
   Web of Science ®Google Scholar
• Artesunate induces apoptosis via a ROS-independent and Bax-mediated intrinsic pathway in HepG2 cells. J Exp Cell Res. 2015;336(2):308–317.
   Web of Science ®Google Scholar
• Wu R, Gao Y, Wu J, Wang C, Yang L. Semi-synthetic product dihydroartemisinin inhibited fibronectin-1 and integrin-β1 and interfered with the migration of HCCLM6 cells via PI3K-AKT pathway. Biotechnol Lett. 2020;42(6):917–926. doi:10.1007/s10529-020-02839-8.
   PubMed Web of Science ®Google Scholar
• Zhang P, Luo H-S, Li M, Tan S-Y. Artesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregulating COX-2. Onco Targets Ther. 2015;8(default):845–854. doi:10.2147/OTT.S81041.
   PubMedGoogle Scholar
• Feng X, Li L, Jiang H, Jiang K, Jin Y, Zheng J. Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells: involvement of apoptosis and autophagy. Biochem Biophys Res Commun. 2014;444(3):376–381. doi:10.1016/j.bbrc.2014.01.053.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen Y, Han J, Meng Q, Xi Q, Wu G, et al. DCAF4L2 promotes colorectal cancer invasion and metastasis via mediating degradation of NFκb negative regulator PPM1B. Am J Transl Res. 2016;8(2):405–418.
   PubMed Web of Science ®Google Scholar
• Lv X, et al. SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling. J Cell Mol Med. 2020;24:10714–10729.
   PubMed Web of Science ®Google Scholar
• Tai D-I, Tsai S-L, Chang Y-H, Huang S-N, Chen T-C, Chang KSS, et al. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer. 2000;89(11):2274–2281. doi:10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2.
   PubMed Web of Science ®Google Scholar
• Su T, Li F, Guan J, Liu L, Huang P, Wang Y, et al. Artemisinin and its derivatives prevent Helicobacter pylori-induced gastric carcinogenesis via inhibition of NF-κB signaling. Phytomedicine. 2019;63:152968. doi:10.1016/j.phymed.2019.152968.
   PubMed Web of Science ®Google Scholar
• Jiang J, Geng G, Yu X, Liu H, Gao J, An H, et al. Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis. Oncotarget. 2016;7(52):87271–87283. doi:10.18632/oncotarget.13536.
   PubMedGoogle Scholar
• Javeed N, Sagar G, Dutta SK, Smyrk TC, Lau JS, Bhattacharya S, et al. Pancreatic cancer-derived exosomes cause paraneoplastic β-cell dysfunction. Clin Cancer Res. 2015;21(7):1722–1733. doi:10.1158/1078-0432.CCR-14-2022.
   PubMed Web of Science ®Google Scholar
• Yu L, Chen JF, Shuai X, Xu Y, Ding Y, Zhang J, et al. Artesunate protects pancreatic beta cells against cytokine-induced damage via SIRT1 inhibiting NF-κB activation . J Endocrinol Invest. 2016;39(1):83–91. doi:10.1007/s40618-015-0328-1.
   PubMed Web of Science ®Google Scholar
• Dong F, Zhou X, Li C, Yan S, Deng X, Cao Z, et al. Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis. Cancer Biol Ther. 2014; 15(11):1479–1488. doi:10.4161/15384047.2014.955728.
   PubMed Web of Science ®Google Scholar
• Bastian  , et al. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013;12:86.
   PubMedGoogle Scholar
• Michl  , et al. Overcoming immune evasion in pancreatic cancer: the combination matters. Gut. 2018;67(6):997–999.
   PubMed Web of Science ®Google Scholar
• Nuclear factor kappa B role in inflammation associated gastrointestinal malignancie. World J Gastroenterol. 2015;(11):3174–3183.
   PubMed Web of Science ®Google Scholar
• Wakefield LM, Hill CSJNRC. Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat Rev Cancer. 2013; 13(5):328–41. doi:10.1038/nrc3500.
   PubMed Web of Science ®Google Scholar
• Wan RJ, Li YHJMMR. MicroRNA-146a/NAPDH oxidase4 decreases reactive oxygen species generation and inflammation in a diabetic nephropathy model. Mol Med Rep. 2018;17(3):4759–4766.
   PubMed Web of Science ®Google Scholar
• Cao Y, Feng Y-H, Gao L-W, Li X-Y, Jin Q-X, Wang Y-Y, et al. Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo. Int Immunopharmacol. 2019;70:110–116. doi:10.1016/j.intimp.2019.01.041.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhou X, Liu J, Gao N, Yang R, Wang Q, et al. Dihydroartemisinin inhibits the tumorigenesis and metastasis of breast cancer via downregulating CIZ1 expression associated with TGF-β1 signaling. Life Sci. 2020; 248:117454. doi:10.1016/j.lfs.2020.117454.
   PubMed Web of Science ®Google Scholar
• B CZa, et al. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. Semin Cancer Biol. 2020; 62:166–181.
   PubMed Web of Science ®Google Scholar
• Yoshida GJ, et al. Activated fibroblast program orchestrates tumor initiation and progression; molecular mechanisms and the associated therapeutic strategies. Int J Mol Sci. 2020;20(9):2256.
   Web of Science ®Google Scholar
• Yoshida GJJJoE. Regulation of heterogeneous cancer-associated fibroblasts: The molecular pathology of activated signaling pathways. J Exp Clin Cancer Res. 2020;39(1):112.
   PubMed Web of Science ®Google Scholar
• Charles J, et al. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19(7):419–435.
   PubMed Web of Science ®Google Scholar
• Yao Y, et al. Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer. J Exp Clin Cancer Res. 2018;37(1):282.
   PubMedGoogle Scholar
• Zhong Z, Virshup DMJMP. Wnt signaling and drug resistance in cancer. Mol Pharmacol. 2019;97(2):72–89.
   PubMed Web of Science ®Google Scholar
• El-Sahli S, et al. Wnt signaling in cancer metabolism and immunity. Cancers. 2019;11(7):904.
   Web of Science ®Google Scholar
• Harb J, Lin PJ, Hao JJCOR. Recent development of Wnt signaling pathway inhibitors for cancer therapeutics. Curr Oncol Rep. 2019; 21(2):12.
   PubMed Web of Science ®Google Scholar
• Zhong G, Liang R, Yao J, Li J, Jiang T, Liu J, et al. Artemisinin ameliorates osteoarthritis by inhibiting the Wnt/β-catenin signaling pathway. Cell Physiol Biochem. 2018;51(6):2575–2590. doi:10.1159/000495926.
   PubMedGoogle Scholar
• Lorini L, Grisanti S, Ambrosini R, Cosentini D, Laganà M, Grazioli L, et al. Antineoplastic activity of artemisinin in adrenocortical carcinoma. Endocrine. 2019; 66(2):425–427. doi:10.1007/s12020-019-02077-7.
   PubMed Web of Science ®Google Scholar
• Hui H-y, Wu N, Wu M, Liu Y, Xiao S-x, Zhang M-f. Dihydroartemisinin suppresses growth of squamous cell carcinoma A431 cells by targeting the Wnt/β-catenin pathway. Anticancer Drugs. 2016; 27(2):99–105. doi:10.1097/CAD.0000000000000307.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang W, Xu J, Li L, Dong Q, Shi Q, et al. Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Oncol Rep. 2013; 30(4):1723–1730. doi:10.3892/or.2013.2658.
   PubMed Web of Science ®Google Scholar
• Li X, et al. The application of exosomal MicroRNAs in the treatment of pancreatic cancer and its research progress. Pancreas. 2021;50(1):12–16.
   PubMed Web of Science ®Google Scholar
• Ren P, Gong F, Zhang Y, Jiang J, Zhang H. MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN. Tumor Biol. 2016;37(3):3215–3225. doi:10.1007/s13277-015-4150-3.
   PubMedGoogle Scholar
• Li Y, Wang Y, Kong R, Xue D, Pan S, Chen H, et al. Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA–mRNA regulatory network. Oncotarget. 2016;7(38):62460–62473. doi:10.18632/oncotarget.11517.
   PubMedGoogle Scholar
• Haijun  , et al. Anti-cancer activity of DHA on gastric cancer—an in vitro and in vivo study. Tumour Biol. 2013;34(6):3791–800.
   PubMedGoogle Scholar
• Shao Y-Y, Zhang T-L, Wu L-X, Zou H-C, Li S, Huang J, et al. AKT axis, miR-21, and RECK play pivotal roles in dihydroartemisinin killing malignant glioma cells. IJMS. 2017;18(2):350. doi:10.3390/ijms18020350.
   Google Scholar